Compare MDU & LGND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MDU | LGND |
|---|---|---|
| Founded | 1924 | 1987 |
| Country | United States | United States |
| Employees | N/A | 68 |
| Industry | Mining & Quarrying of Nonmetallic Minerals (No Fuels) | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.9B |
| IPO Year | N/A | 1992 |
| Metric | MDU | LGND |
|---|---|---|
| Price | $19.26 | $184.82 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $22.00 | ★ $144.71 |
| AVG Volume (30 Days) | ★ 2.4M | 139.7K |
| Earning Date | 11-06-2025 | 08-05-2025 |
| Dividend Yield | ★ 2.91% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $1,876,593,000.00 | $181,488,000.00 |
| Revenue This Year | $9.10 | $18.41 |
| Revenue Next Year | $3.08 | $18.87 |
| P/E Ratio | $21.41 | ★ N/A |
| Revenue Growth | N/A | ★ 53.40 |
| 52 Week Low | $15.04 | $81.74 |
| 52 Week High | $21.49 | $129.90 |
| Indicator | MDU | LGND |
|---|---|---|
| Relative Strength Index (RSI) | 36.44 | 38.34 |
| Support Level | $20.27 | $192.71 |
| Resistance Level | $21.34 | $201.49 |
| Average True Range (ATR) | 0.36 | 6.84 |
| MACD | -0.24 | -2.89 |
| Stochastic Oscillator | 2.12 | 3.79 |
MDU Resources Group Inc operates in three business segments, which include the electric segment, which generates, transmits, and distributes electricity in Montana, North Dakota, South Dakota, and Wyoming; The natural gas distribution segment distributes natural gas in those states, as well as in Idaho, Minnesota, Oregon, and Washington; The pipeline segment provides natural gas transportation and underground storage services through a regulated pipeline system in the Rocky Mountain and northern Great Plains regions of the United States.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.